Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Curvebeam AI Ltd. ( (AU:CVB) ) has issued an update.
CurveBeam AI Limited has received the first A$4 million tranche of a strategic investment of up to A$10 million from Shandong WeiYing Intelligent Medical Technology, a subsidiary of leading Chinese orthopaedic device group WEGO Orthopaedics, to support a long-term joint venture and expansion into the Chinese market. The initial funding, issued at A$0.405 per share – roughly five times CurveBeam AI’s last traded price – significantly strengthens the company’s balance sheet and underpins its global growth strategy, providing a pathway to pursue long-term revenue growth and royalty streams from one of the world’s largest healthcare markets, while tying its advanced imaging and AI solutions to a major domestic orthopaedic partner in China.
The most recent analyst rating on (AU:CVB) stock is a Hold with a A$0.15 price target. To see the full list of analyst forecasts on Curvebeam AI Ltd. stock, see the AU:CVB Stock Forecast page.
More about Curvebeam AI Ltd.
CurveBeam AI Limited, listed on the ASX under ticker CVB, is a medical technology company that develops, manufactures and sells specialised point-of-care CT imaging equipment alongside AI-enabled SaaS clinical assessment tools for managing musculoskeletal conditions. Its flagship HiRise scanner provides both weight-bearing and traditional CT scans, positioning the company as an innovative player in advanced orthopaedic imaging, with corporate operations and AI/IP functions based in Melbourne, Australia, and global operations headquartered in Hatfield, Pennsylvania, USA.
Average Trading Volume: 949,830
Technical Sentiment Signal: Sell
Current Market Cap: A$38.36M
Find detailed analytics on CVB stock on TipRanks’ Stock Analysis page.